Pluri Says US NIAID Will Provide Company With $1.4M From July 1, 2024 To June 30, 2025; NIAID Exercised Its Option For Year Two Of The Three-year $4.2M Contract It Entered Into With Pluri In July 2023
Portfolio Pulse from Benzinga Newsdesk
Pluri announced that the US NIAID will provide the company with $1.4M from July 1, 2024, to June 30, 2025, as part of a three-year $4.2M contract. The funding will support the manufacturing and studies of PLX-R18 cell therapy for treating hematopoietic complications of acute radiation syndrome.
June 06, 2024 | 10:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pluri has secured $1.4M in funding from the US NIAID for the second year of a three-year $4.2M contract. This funding will support the development of PLX-R18 cell therapy for treating hematopoietic complications of acute radiation syndrome.
The additional funding from NIAID is a positive development for Pluri, as it ensures continued financial support for the development of PLX-R18. This could lead to advancements in their cell therapy product, potentially increasing investor confidence and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100